SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ArQule
ARQL 20.000.0%Jan 16 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (83)7/18/1997 2:29:00 AM
From: James Silverman   of 399
 
Miljenko,

ARQL is doing all these collaborations because their technology is the best in the business. There is certainly a danger of "overreaching", but with 55 mm in the bank, the chemical synthesis can be expanded, especially with their present experience in combi-chem. Also, with the 15 targets that WE has presented to ARQl, the possibilities are enormous for milestones and royalties. I view this not as a negative but a huge validation of their drug development and optimization technologies.

Cheers! Jim Sol.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News